ANI Pharmaceuticals, Inc. (ANIP)

NGM – Real Time Price. Currency in USD

74.27

-0.26 (-0.35%)

Market open: Aug 12, 2026, 2:05 PM EDT

74.53

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

10.08.2026

ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut

ANI Pharmaceuticals tops Q2 earnings and sales estimates, but shares fall as the company cuts its 2026 Cortrophin Gel revenue outlook.

10.08.2026

These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results

ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported upbeat earnings for the second quarter on Friday.

07.08.2026

ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript

07.08.2026

Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

07.08.2026

ANI Pharmaceuticals Q2 Earnings Call Highlights

ANI Pharmaceuticals NASDAQ: ANIP reported record second-quarter revenue and adjusted EBITDA as growth in its Cortrophin Gel rare-disease franchise and generics business lifted results, while the company modestly reduced its full-year Cortrophin revenue outlook to reflect first-half performance.

07.08.2026

ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates

ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.21 per share, beating the Zacks Consensus Estimate of $2.01 per share. This compares to earnings of $1.8 per share a year ago.

07.08.2026

ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results

Quarterly net revenues of $266.0 million, an increase of 25.9% year-over-year Purified Cortrophin ® Gel net revenues of $117.1 million, an increase of 43.5% year-over-year Quarterly GAAP net income available to common shareholders of $24.7 million; Quarterly adjusted non-GAAP EBITDA of $71.6 million, an increase of 32.4% year-over-year Diluted GAAP income per share of $1.05 and adjusted non-GAAP diluted earnings per share of $2.21 Reaffirming 2026 guidance for total net revenue of $1,080 - $1,140 million and adjusted non-GAAP EBITDA of $285 - $300 million PRINCETON, N.J., Aug. 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the second quarter ended June 30, 2026.

Videos

No Data

There is no data to display

Press releases

07.08.2026

ANI Pharmaceuticals, Inc. (ANIP)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

ANI Pharmaceuticals, Inc. (ANIP)

ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut

These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results

ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript

Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics

ANI Pharmaceuticals Q2 Earnings Call Highlights

ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates

ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results

Videos

No Data

Press releases

ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results

ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut

These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results

ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript

Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics

ANI Pharmaceuticals Q2 Earnings Call Highlights

ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates

ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results

Videos

No Data

Press releases

ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results

Search stocks

ANI Pharmaceuticals, Inc. (ANIP)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

ANI Pharmaceuticals, Inc. (ANIP)

ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut

These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results

ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript

Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics

ANI Pharmaceuticals Q2 Earnings Call Highlights

ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates

ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results

Videos

No Data

Press releases

ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results

ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut

These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results

ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript

Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics

ANI Pharmaceuticals Q2 Earnings Call Highlights

ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates

ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results

Videos

No Data

Press releases

ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results